Unbiased Analysis of Today's Healthcare Issues
Today I participated in a fantastic panel presentation at the 2018 Academy of Managed Care & Specialty Pharmacy Conference in Boston. Moderated by Jonathan Collar of Cigna-Health Spring, the session discussed “New Tools for Measuring Treatment Value in Rheumatoid Arthritis“. My co-presenters were Jeroen Jansen from the Innovation and Value Initiative and Dr. Jeff Curtis, a…
This paper–written with co-authors Mintu P. Turakhia, Katalin Bognar, Jeffrey Trocio, Younos Abdulsattar, Daniel Wiederkehr, and Dana P. Goldman–is now up at PLOS One. The study abstract is pasted below. Introduction As atrial fibrillation (AF) is often asymptomatic, it may remain undiagnosed until or even after development of complications, such as stroke. Consequently the observed…
That is the title of my latest blog post in Health Affairs with co-author Mark Linthicum. The premise is as follows: CVS recently announced its new Transform Rheumatoid Arthritis Care initiative, which aims to reshape coverage of rheumatoid arthritis care through “value-based management strategies including outcomes based contracts and a new indication-based formulary for autoimmune…
This is the title of a recent paper by myself and co-authors Mina Kabiri, Michelle Brauer, Jeff Sullivan, Thomas M. Gill, and Dana P. Goldman published in Value in Health. The abstract of the paper is below, but do read the whole thing. Background Mobility impairments have substantial physical and mental health consequences, resulting in diminished…
That is the title of my latest article in Pharmaceutical Market Europe. An excerpt is below. Randomised controlled trials (RCTs) are regarded as the gold standard of scientific evidence, and for good reason. By randomizsing a treatment across study arms, RCTs eliminate patient-treamtent selection bias, resulting in reliable causal inference. In contrast, in the real…
Along with my co-authors Jeff Sullivan, Jacki Chou, Michael Neely, Justin Doan, and Ross Maclean I am happy to announce to publication our paper “The effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma” in Cancer Management and Research. The abstract is below. Objective: To examine how observed medication nonadherence to 2…
With the FDA’s introduction of new guidelines surrounding the use of real-world evidence (RWE) in medical device regulatory decisions, FDA Commissioner Scott Gottlieb advances the argument for the utility of RWE. In fact, the FDA is currently considering the role of RWE in evaluating pharmaceutical treatments. Despite much debate over what part RWE should play in…
That’s the title of my article released today in U.S. News and World Report. Here is an excerpt. A number of health care industry leaders are making big bets that the future of health care lies in precision medicine. This July, Dr. Priscilla Chan and Mark Zuckerberg donated $10 million to the University of California-San Francisco’s…
In a recent paper with Jeff Sullivan, Dana P. Goldman, and Thomas M. Gill in PLOS One, we try to answer this question. The paper’s abstract is below. Introduction Chronic diseases associated with aging, such as arthritis, frequently cause reduced mobility, pain and diminished quality of life. To date, research on the association between…
Below is the abstract for my most recent publication titled “Access to credible information on schizophrenia patients’ medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers“. It is work with Suepattra G May, Anshu Shrestha, Charles Ruetsch, Nicole Gerlanc, Felicia Forma, Ainslie Hatch, Darius N Lakdawalla, and Jean-Pierre Lindenmayer.…